BERCI
BERCI
Beraprost et Claudication Intermittent. A phase-III clinical trial assessing the effect of beraprost, an oral prostaglandin PGI2 analogue with antiplatelet and vasodilating properties, on the outcome of patients with intermittent claudication.Results
Beraprost was associated with an increase in pain-free walking distance and a non-significant reduction in critical cardiovascular events.